Secret Life of a Cancer-Related Protein Revealed by 3D Structure
News Aug 12, 2013
The finding, published today in Nature Structural and Molecular Biology, stems from the first 3D structure of the protein’s active core, and opens up new avenues for drug design.
“Everybody thought this protein was a tumour-suppressor,” says Daniel Panne, who led the work, “but we’ve found that some mutations make it an oncogene – a gene that turns the cell cancerous – which actually makes it a viable drug target.”
Surprisingly, the finding reveals that mutations to this protein that have been linked to cancer can act in two different ways. As expected, some mutations make this ‘fireman’ protein – known as p300 – unable to put out the fire: they cause it to malfunction and lose control over other genes, thwarting its tumour-suppressor role. But, as Panne and colleagues discovered, some cancer-linked mutations actually make p300 into an arsonist: they make it hyperactive, turning it into an oncogene. Which mutations are which? The secret lies in an unexpected piece of the puzzle.
In this study, Panne and colleagues determined the structure of the whole of the protein’s active core – the part that physically interacts with genetic material to control genes – for the first time. They found that this 3D puzzle had one more piece than expected. p300 has a groove that it uses to slot onto the cell’s genetic material to activate or inactivate genes, and the EMBL scientists found that, sitting on top of that groove like a lid, was a piece no-one knew this protein had. This ‘lid’ is like a built-in self-control mechanism. It determines whether the protein can slot onto genetic material or not: for p300 to do its job, it has to open the lid. But if a mutation interferes with the lid, keeping it permanently open, the protein will go into over-drive, and the resulting uncontrolled gene activity can lead to cancer.
Tumours caused by these hyper-activating mutations could potentially be fought by drugs that inhibit p300. So, armed with the knowledge of the protein’s structure, the EMBL scientists now plan to investigate how to thwart p300 when it goes from fireman to arsonist.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE